• Ascentage Pharma Group International flagged 17 clinical updates on two lead blood-cancer drugs for presentation at European Hematology Association Congress in Stockholm on June 11-14, 2026.
• Data will be shown from ongoing studies of olverembatinib in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, including a global registrational Phase 3 program in newly diagnosed patients.
• Separate abstracts will outline lisaftoclax results in chronic lymphocytic leukemia or small lymphocytic lymphoma, including factors linked to patient outcomes in a pivotal Phase 2 study.
• Early-stage combination data pairing olverembatinib with lisaftoclax in pediatric relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia will also be presented, with focus on safety profile and initial signs of activity.
• Both assets remain investigational in US market, limiting near-term commercialization there while the company builds an international clinical evidence package.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.